oxadiazoles and Leukemia--Erythroblastic--Acute

Leukemia is distinguished by abnormal proliferation of leukocytes. Although there has been some progress in developing novel cancer therapies, no significant improvement was observed in the overall survival rate over the last decade. Selective cyclooxygenase-2 (COX-2) inhibitors are known to inhibit tumor growth by exerting antimetastatic and antiangiogenic effects through inhibition of COX -dependent and independent pathways. The ability of two new triaryl-oxadiazole derivatives, compounds A (3-(4-chlorophenyl) -5-(4-flurophenyl)-4-Phenyl-4,5-dihydro-1,2,4-oxadiazole) and B (3,5-bis(4-chlorophenyl)-4-Phenyl-4,5-dihydro-1,2,4-oxadiazole), to induce apoptosis in human erythroleukemia K562 cells was evaluated and the upstream mechanism was investigated.. K562 cells were treated with compounds A and B at their IC50 concentrations and analyzed by DAPI staining and Annexin-V-FLUOS labelling solution. Nuclear factor kappa-B (NF-κB) activation was evaluated by TransAM kit. Cyclooxygenase-2 (COX-2), Caspase-3, Bax, Bcl-2, ferritin heavy chain (FHC), extra cellular signal-regulated kinase (ERK), p-ERK and early growth response protein-1 (Egr1) levels were determined using Western blotting, while c-Myc mRNA level was investigated by RT-PCR.. Changes in nuclear morphology and the increased annexin-V/PI staining revealed the apoptotic cell death in compounds A- and B-treated K562 cells. A significant reduction in NF-κB activity as well as FHC and p-ERK levels were detected in these cells. No change was observed in the levels of Bax, Bcl-2, Caspase-3, COX-2, c-Myc and Egr1, following treatment with the two compounds. Collectively, compounds A and B potentiate apoptosis as shown by DAPI staining, flowcytometry, FHC and p-ERK downregulation and NF-κB inactivation.. Two compounds induce apoptosis in a COX-2-independent manner which also appears to be independent from mitochondria, caspase and c-Myc/Egr1 pathways.

Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Erythroblastic, Acute; NF-kappa B; Oxadiazoles; Proto-Oncogene Proteins c-myc; Signal Transduction

NBD-taurine [N-(7-nitrobenzofuran-4-yl) taurine], a fluorescent substrate for the human erythrocyte anion exchange system, has been used to test the feasibility of making flow cytometric measurements of anion transport in K562 erythroleukemic cells. Cells were preloaded by incubation with 20 microM-2mM NBD-taurine, then diluted 10-30-fold, and efflux was monitored by measuring fluorescence intensity (FL) as a function of time using excitation at 488 nm. The observed rate of decrease in fluorescence was sensitive to temperature and also to phloretin, a compound known to inhibit anion transport and other carrier-mediated transport processes. The coefficient of variation (CV) of the fluorescence distribution increased markedly over the efflux period, suggesting heterogeneity of the K562 population with respect to the rate constant for NBD-taurine efflux. This heterogeneity was also reflected in the upward curvature of a first order plot of log (FLt - FL infinity) versus time. Half-times calculated from initial linear portions of the first-order plots were found to decrease as the loading concentration of NBD-taurine was decreased, as predicted for a saturable transport system. NBD-taurine is not an ideal anion transport substrate for flow cytometric studies. It appears to bind to high-affinity sites within the cells with consequent fluorescence quenching, complicating interpretation of kinetic curves at low concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Anions; Cell Line; Cell Membrane; Flow Cytometry; Humans; Kinetics; Leukemia, Erythroblastic, Acute; Oxadiazoles; Taurine